December 2019 - Global Life Science Business Partnering - News & Updates

Highlights of December 2019

  1. India based Akums Drugs receives investment of US$70 million from Quadria Capital.
  2. Eris Lifesciences buys anti-diabetes novel drug Zomelis in India for US$13 Million.
  3. Alkem Labs to acquire assets related to Dronabinol for over US$10 Million from AbbVie Inc.
  4. Mankind Pharma inks pact with Glenmark for anti-diabetes drug.
  5. Cipla acquires brand, trademark for anti-diabetic drug Vysov in India.
  6. Biocon extends licensing pact with Equillium for itolizumab.
  7. Piramal Pharma Solutions collaborates with BerGenBio ASA to develop bemcentinib for the treatment of elderly patients with recurrent acute myeloid leukemia (AML).
  8. Turnstone teams up with Takeda in US$900 Million deal to work on biotech's oncolytic drug.
  9. Rheos Medicines has sealed a near US$800 Million biobucks deal with Swiss major Roche to seek out and develop new meds for autoimmune and inflammatory diseases.
  10. Sanofi trades Seprafilm unit to Baxter for US$350 Million in cash ahead of strategy launch.
  11. Rapt Therapeutics is handing Hanmi Pharmaceutical the rights to its lead cancer program in South Korea and greater China in exchange for US$10 Million upfront and the promise of millions more in milestones.
  12. Orexo acquires US rights to commercialize vorvida, a digital therapy for the treatment of Alcohol Use Disorder (AUD), from GAIA.

Updates at Aagami

  1. We wish you a very happy, healthy and successful 2020.
  2. Aagami is geared up to attend JP Morgan Healthcare Conference and Biotech Showcase (January 13-15, 2020). Few time options left in the meeting calendar of the partnering system. If you would like to meet, please contact us immediately at godwyn@aagami.com

Some of the Client opportunities that Aagami is representing during JPM week are:

  1. Available for Licensing: DriDose® - a Platform Technology for the delivery of a dry powder drug formulation into the nasal cavity.
  2. Available for Licensing: Diabetic drug for the treatment of severe hypoglycaemic reactions using Dridose® nasal dry powder formulation; successfully completed a proof of concept clinical trial.
  3. Available for IP Acquisition: Next-Generation PEGylation(PharmaPEG®) technology & associated assets.
  4. Seeking Investment / Partnering: Drug to treat alcohol poisoning(Breakthrough, life-saving); Another Drug to prevent hangover and Asian Flush; quick to market solution which works safely and efficiently.
  5. Seeking Investment & Partnering: Algae Technology - for Beta Carotene, Lutein, DHA and others (Innovative Process and Cost Optimized).
  6. Available for Licensing: Selection Technology using Bacteriocin-Immunity for Improved Microbial (E. coli.) Fermentation.
×
Twitter